Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

However, while Wegovy is prescribed by the NHS for weight management, Rybelsus is not licensed for such and is only available as a treatment for Type 2 diabetes. There are other limitations too. In ...

Prediabetes is almost always a precursor to type 2 diabetes — but it doesn’t have to lead to that outcome. Experts share healthy steps to reverse the condition.

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

The study is the first set of global estimates directly linking diabetes prevalence with treatment coverage over a ...